A national search for cases of Buruli ulcer in Ghana identified 5,619 patients, with 6,332 clinical lesions at various stages. The overall crude national prevalence rate of active lesions was 20.7 per 100,000, but the rate was 150.8 per 100,000 in the most disease-endemic district. The case search demonstrated widespread disease and gross underreporting compared with the routine reporting system. The epidemiologic information gathered will contribute to the design of control programs for Buruli ulcer.
Mycobacterium ulcerans disease is common in some humid tropical areas, particularly in parts of West Africa, and current management is by surgical excision of skin lesions ranging from early nodules to extensive ulcers (Buruli ulcer). Antibiotic therapy would be more accessible to patients in areas of Buruli ulcer endemicity. We report a study of the efficacy of antibiotics in converting early lesions (nodules and plaques) from culture positive to culture negative. Lesions were excised either immediately or after treatment with rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2, 4, 8, or 12 weeks and examined by quantitative bacterial culture, PCR, and histopathology for M. ulcerans. Lesions were measured during treatment. Five lesions excised without antibiotic treatment and five lesions treated with antibiotics for 2 weeks were culture positive, whereas three lesions treated for 4 weeks, five treated for 8 weeks, and three treated for 12 weeks were culture negative. No lesions became enlarged during antibiotic treatment, and most became smaller. Treatment with rifampin and streptomycin for 4 weeks or more inhibited growth of M. ulcerans in human tissue, and it provides a basis for proceeding to a trial of antibiotic therapy as an alternative to surgery for early M. ulcerans disease.
Buruli ulcer is a disease of skin and soft tissue caused by Mycobacterium ulcerans. It can leave affected people scarred and disabled. What are the prospects for disease control?
Abstract. This study examines some of the socioeconomic cost of treating 102 cases of Buruli ulcer between 1994 and 1996 at the St. Martin's Catholic Hospital in Agroyesum in the Amansie West district of the Ashanti region of Ghana. Seventy percent of the cases were children (up to 15 years of age). There was no sex difference in the distribution of cases. Hospitalization was prolonged (average ϭ 186 days in 1994, 103 days in 1995, and 102 days in 1996) with no significant age and sex differences. There were 10 limb amputations, 12 patients were left with contracture deformities, one patient lost sight in one eye, and two died of sepsis and tetanus. The average total treatment cost per patient was $966.85 (62% indirect) in 1994, $706.08 (75% indirect) in 1995, and $658.74 (79% indirect) in 1996. With increasing number of cases, high treatment costs, and serious complications, urgent attention should be given to the disease in terms of control and research efforts aimed at early detection and treatment.
We have evaluated the clinical efficacy of the combination of oral rifampin at 10 mg/kg of body weight and intramuscular streptomycin at 15 mg/kg for 8 weeks (RS8), as recommended by the WHO, in 160 PCRconfirmed cases of Mycobacterium ulcerans disease. In 152 patients (95%) with all forms of disease from early nodules to large ulcers, with or without edema, the lesions healed without recourse to surgery. Eight patients whose ulcers were healing poorly had skin grafting after completion of antibiotics. There were no recurrences among 158 patients reviewed at the 1-year follow-up. The times to complete healing ranged from 2 to 48 weeks, according to the type and size of the lesion, but the average rate of healing (rate of reduction in ulcer diameter) varied widely. Thirteen subjects had positive cultures for M. ulcerans during or after treatment, but all the lesions healed without further antibiotic treatment. Adverse events were rare. These results confirm the efficacy of RS8 delivered in a community setting.Mycobacterium ulcerans disease, known as Buruli ulcer, is a chronic subcutaneous infection which is common in humid rural tropical areas. The majority of patients are children aged less than 15 years living in rural areas remote from a hospital (29). Infection initially manifests as a painless nodule or plaque which breaks down centrally to form an ulcer with undermined edges (11). In a small proportion of lesions, there is edema around the ulcer which spreads rapidly, resulting in a very large ulcer. Significant morbidity results from Mycobacterium ulcerans disease when there is extensive scarring or functional limitation from contractures at joints, and there is occasionally a need for amputation of a limb. Ulcers or scars rarely undergo malignant transformation (12).Until recently, the mainstay of treatment for Buruli ulcer was excision of lesions with a wide margin to ensure complete removal of infected tissue. Recurrence rates after surgery varied between 6 and 17%, depending on the type and extent of the lesion and on the experience and skill of the surgeon (1,6,22). Recent evidence that antibiotics are effective has shifted the balance between surgery and antibiotics. In vitro, M. ulcerans has been shown to be susceptible to rifampin (13), aminoglycosides (7), macrolides (21), and quinolones (26). Infection of mouse footpads has been used as a model for susceptibility testing, and after treatment with the same antibiotics, the lesions became smaller and the total number of M. ulcerans organisms in tissue was reduced (2,8,25). The combination of rifampin with amikacin or streptomycin for 8 weeks has been the most effective in reducing the bacterial load in a number of studies, and the low relapse rate after treatment suggested that this combination was bactericidal (2, 15). An important reason for using more than one drug is that resistant mutants were found after rifampin monotherapy in mice (16).The bactericidal effect of rifampin at 10 mg/kg of body weight orally combined with streptomycin at 15 mg/k...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.